Send us Feedback

Eli Lilly and Company (LLY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

LLY » Topics » Asset Impairments and Related Restructuring and Other Special Charges (Notes 5 and 14)

These excerpts taken from the LLY 10-K filed Feb 27, 2009.
Asset Impairments and Related Restructuring and Other Special Charges (Notes 5 and 14)
 
•  We recognized asset impairments, restructuring, and other special charges of $190.6 million (pretax), which decreased earnings per share by $.12. These charges were primarily associated with previously announced strategic decisions affecting manufacturing and research facilities.
 
•  We incurred a special charge following a settlement with one of our insurance carriers over Zyprexa product liability claims, which led to a reduction of our expected product liability insurance recoveries, and other product liability charges. This resulted in a charge totaling $111.9 million (pretax), which decreased earnings per share by $.09.
 
Asset
Impairments and Related Restructuring and Other Special Charges
(Notes 5 and 14)


 























• 
 We recognized asset impairments, restructuring, and other
special charges of $190.6 million (pretax), which decreased
earnings per share by $.12. These charges were primarily
associated with previously announced strategic decisions
affecting manufacturing and research facilities.
 
• 
 We incurred a special charge following a settlement with one of
our insurance carriers over Zyprexa product liability claims,
which led to a reduction of our expected product liability
insurance recoveries, and other product liability charges. This
resulted in a charge totaling $111.9 million (pretax),
which decreased earnings per share by $.09.


 




EXCERPTS ON THIS PAGE:

10-K (2 sections)
Feb 27, 2009

RELATED TOPICS for LLY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki